Medoit

[Eren Chen @ErenChenAI]

A Chinese girl DIY’d a gear-driven 3D-printed Medusa, and it’s oddly mesmerizing to watch. 👀

[Jacob Plieth @JacobPlieth]

"Rapid" Car-T manufacturing? It's more about product quality, less about speed. $GILD data at #ASH25 via @ApexOnco -> https://t.co/xCQTZN1RBQ

[Ben Derman @bdermanmd]

My top 11 myeloma/amyloidosis abstracts I’m excited about, spanning bispecifics, CAR T, MRD and amyloid clearance. Stay tuned for a much longer discussion at the end re: MajesTEC-3...

1) Abstract 94 (@End_myeloma): CARTITUDE-4 Long-term PFS with cilta-cel in standard-risk patients showed a 30-month PFS rate of 71% (ITT) and 80.5% (as-treated).
🤔It would be good to know the breakdown by lines of therapy.
🚨We need to continue having conversations with patients about cilta-cel as early as second line as we find ways to reduce delayed toxicities.

[City Xtra @City_Xtra]

𝗢𝗨𝗥 𝗠𝗔𝗡𝗔𝗚𝗘𝗥!!! 🤫💙

[Medoit @looloodoit]

@adamfeuerstein it is very misleading. China CDE initiated reform in 2015-2016. totally different world since then，in terms of study conduct process and quality.

[Dr. Iván R. González @Dr_Ivanoncologo]

This #article analyses the landscape of approved and investigational therapies that target #kinases and trends within it, including the most #popular targets of kinase
inhibitors and their expanding range of indications
#Congratulation 🎉and thank you Dr Raut @oncologician ‼️

[Dr. Paul De Santis, PharmD @DrPaulyDeSantis]

#ASCO21 #CLL ELEVATE-RR Acala vs. Ibr: No difference in efficacy🚫. Acala Safety is different, but not better vs. Ibr. Acala: More Gr3+ Pneumonia, Afib, and Thrombocytopenia⛔️; Ibr: More Gr3+ HTN, Diarrhea, Neutropenia. #lymsm

[Manni Mohyuddin @ManniMD1]

Observation is NOT standard of care for patients with myeloma post auto. In Europe or the US.

The failure of daratumumab to prolong "PFS" against "observation" arm in patients that previously received dara-VTD is a profound result with important implications for the US.

#mmsm

[Jacob Plieth @JacobPlieth]

Still not quite the allo Car-T knockout blow from $ALLO, but it is progress at long last. @evaluatevantage take on #ASCO21 & "CD19 forum" data yesterday https://t.co/qS8tArex3N $CLLS

[MDS Hub @MDS_Hub]

💊 Does CC-486 (oral azacitidine) improve outcomes in patients with LR-MDS?

Read here:
👉 https://t.co/FrcTMvsfem 👈

#mds #mdssm #hematology

[Vinay Prasad MD MPH @VPrasadMDMPH]

First line therapy
High risk myeloma
Maintenance
with @rajshekharucms @bdermanmd @ManniMD1 @rubinstein_md @drkevinknopf

After a heated twitter conversation, we have a myeloma roundtable to 'settle' the debate
🔥🔥🔥
https://t.co/Eu0HwcaZIJ

[Pankaj P @pankajp46813096]

@HadidiSamer https://t.co/TF4rPxmIoR nicrely explained by @AaronGoodman33 @VPrasadMDMPH

[John Carroll @JohnCendpts]

#3
Gene therapy trial is derailed after getting hit by the latest serious adverse event in the field — shares crash
https://t.co/sa9QFuPTBQ

[Jacob Plieth @JacobPlieth]

Some thoughts on the outcome of this week's adcom, with a handy summary of pros and cons. Via @evaluatevantage https://t.co/hTa7OwZCxi

[Medoit @looloodoit]

@biotech3 没看懂

[Jacob Plieth @JacobPlieth]

A sumnmary of @evaluatevantage 's #AACR21 coverage. Bonus! Features a recording of my @BiotechCH preview chat with @bradloncar https://t.co/abPr0u0lTj

[Jacob Plieth @JacobPlieth]

Re Friday's $BMY $BLUE approval of Abecma (ide-cel) here's an excellent thread on BCMA therapies https://t.co/yuux2LDTOW

[Plenary Session Podcast 🎙️ @Plenary_Session]

Episode 3.43 just dropped!

We take a deep dive into the findings of the Beat AML Master Trial. Did they beat AML? Listen and find out!

Back us on Patreon! https://t.co/FTUdi7ZRkn
Sign up for our mailing list: https://t.co/J5BrgeGX13
https://t.co/kkOTC8PdfW

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

The Role of MRD in Multiple Myeloma [Dec 10, 2020] ASTCT Talks - ... the official podcast of the American Society for Transplantation and Cellular Therapy (@ASTCT) - 1) @Phari 2) Dilan Patel, 3) Lia Gore https://t.co/IET7AlD8u9 #mmMRD #mmsm #ALLsm #leusm

[Jonathan Friedberg @DrJFriedberg]

Dr Wang: VLS-101 phase 1 with responses, including complete responses #ASH2020 My colleague Dr Barr enrolling patients ⁦@WilmotCancer⁩